マーケットレポート詳細
初代細胞の世界市場：タイプ別、ヒト/動物由来別2028年予測
Primary Cells Market by Type (Hematopoietic, Dermatocytes, Hepatocytes, Gastrointestinal, Lung, Renal, Heart, Musculoskeletal), Origin (Human Primary Cells, Animal Primary Cells), End User (Pharma Biotech, CROs, Academia), Region - Global Forecast to 2028
- 出版元：MarketsandMarkets
出版元について - 発行年：2023年7月
- 定価 ：Single User License(1名様ライセンス)US$4,950(米国ドル)/ Multi User License(5名様)$6,650 / Corporate User License $8,150
- ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
- ご請求は円換算（お見積り日TTSレート）となります。
- 納品形態：PDF by Email
- 当調査レポートは英文217ページになります。
- 商品コード：MAM3312
お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。
【レポート紹介】
初代細胞の世界市場規模は2023年で17億ドル、2028年に28億ドル、市場の平均年成長率は10.5%で推移する見通しです。
レポートは初代細胞の世界市場について2028年までの市場予測データ(金額US$)を掲載しています。同市場をさまざまな区分で細分化し、そのセグメント市場ごとの市場予測（タイプ別市場、由来別市場、等）を中心に構成されています。また競合状況、主要企業情報（13社）、バリューチェーン分析、エコシステム分析などの分析も加味し、初代細胞市場の動向および今後成長性を詳細にレポートしています。
【レポート構成概要】
◆初代細胞の世界市場予測2021-2028年
・市場規模(US$)
◆タイプ別、市場-2028年
造血細胞
皮膚糸状菌
消化管細胞
肝細胞
・冷凍保存肝細胞
・フレッシュ肝細胞
肺細胞
腎細胞
心臓細胞
筋骨格細胞
その他初代細胞
※(市場規模US$)
◆由来別、市場-2028年
・ヒト初代細胞
・動物初代細胞
※(市場規模US$)
◆エンドユーザー別、市場-2028年
・製薬/バイオテクノロジー企業/CRO
・学術/研究機関
・その他エンドユーザー
※(市場規模US$)
◆主要国地域別市場-2028年
北米
・米国、カナダ
欧州
・英国、ドイツ、フランス、イタリア
・その他欧州
アジア太平洋
・日本、中国
・その他アジア太平洋
その他地域
※国地域別に全セグメントの細分化データ掲載、詳細は目次参照
◆市場分析
・市場ダイナミクス（促進要因、障壁、機会、課題）
・プライシング分析
・バリューチェーン分析
・サプライチェーン分析
・エコシステム分析
・技術分析
・業界構造分析
・競合状況
・市場シェア分析
◆初代細胞の主要企業プロフィール動向
・THERMO FISHER SCIENTIFIC, INC.
・MERCK KGAA
・CORNING INCORPORATED
・LONZA GROUP
・CHARLES RIVER LABORATORIES, INC.
・PROMOCELL GMBH
・AMERICAN TYPE CULTURE COLLECTION (ATCC)
・CELL BIOLOGICS, INC.
・ZENBIO, INC.
・STEMCELL TECHNOLOGIES, INC.
・ALLCELLS
・IXCELLS BIOTECHNOLOGIES
・NEUROMICS
その他企業
・AXOL BIOSCIENCE LTD.
・STEMEXPRESS
・BIOIVT
・SCIENCELL RESEARCH LABORATORIES, INC.
・AMSBIO
・PROMAB BIOTECHNOLOGIES, INC.
・CREATIVE BIOARRAY
・BPS BIOSCIENCE, INC.
・EPITHELIX
・REACHBIO RESEARCH LABS
・ACCEGEN
・KOSHEEKA
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】
Table of Contents (英文詳細目次）
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE 27
1.3.1 MARKETS COVERED 27
1.3.2 YEARS CONSIDERED 28
1.4 CURRENCY
1.5 LIMITATIONS 28
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.8 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
・ FIGURE 1 PRIMARY CELLS MARKET: RESEARCH DESIGN
2.1.1 SECONDARY RESEARCH
2.1.2 PRIMARY RESEARCH 33
・ FIGURE 2 PRIMARY CELLS MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
・ FIGURE 3 PRIMARY CELLS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
・ FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 – REVENUE SHARE ANALYSIS (2022)
・ FIGURE 5 ILLUSTRATIVE EXAMPLE OF MERCK KGAA: REVENUE SHARE ANALYSIS (2022)
・ FIGURE 6 KEY INDUSTRY INSIGHTS
2.3 GROWTH FORECAST
・ FIGURE 7 PRIMARY CELLS MARKET: CAGR PROJECTIONS, 2023–2028
・ FIGURE 8 PRIMARY CELLS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
・ FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 RECESSION IMPACT
・ TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024–2028 (% GROWTH)
・ TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
・ TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
3 EXECUTIVE SUMMARY
・ FIGURE 10 PRIMARY CELLS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
・ FIGURE 11 PRIMARY CELLS MARKET, BY ORIGIN, 2023 VS. 2028 (USD MILLION)
・ FIGURE 12 PRIMARY CELLS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
・ FIGURE 13 GEOGRAPHICAL SNAPSHOT OF PRIMARY CELLS MARKET
4 PREMIUM INSIGHTS
4.1 PRIMARY CELLS MARKET OVERVIEW
・ FIGURE 14 GROWING GLOBAL INCIDENCE OF CANCER TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: PRIMARY CELLS MARKET, BY END USER AND COUNTRY (2022)
・ FIGURE 15 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS DOMINATED NORTH AMERICAN PRIMARY CELLS MARKET IN 2022
4.3 PRIMARY CELLS MARKET SHARE, BY TYPE, 2023 VS. 2028
・ FIGURE 16 HEMATOPOIETIC CELLS SEGMENT TO DOMINATE MARKET IN 2028
4.4 PRIMARY CELLS MARKET SHARE, BY ORIGIN, 2022
・ FIGURE 17 HUMAN PRIMARY CELLS SEGMENT DOMINATED MARKET IN 2022
4.5 PRIMARY CELLS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
・ FIGURE 18 ASIA PACIFIC COUNTRIES TO REGISTER HIGH GROWTH RATES FROM 2023 TO 2028
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
・ FIGURE 19 PRIMARY CELLS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
・ TABLE 4 PRIMARY CELLS MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 INCREASING CANCER RESEARCH
・ TABLE 5 PROJECTED INCREASE IN NUMBER OF CANCER PATIENTS, 2015 VS. 2018 VS. 2020 VS. 2035
・ TABLE 6 ESTIMATED NUMBER OF NEW CASES OF ALL CANCERS (EXCLUDING NON-MELANOMA SKIN CANCER) FOR BOTH SEXES, 2020 VS. 2040
5.2.1.2 ADVANTAGES OF PRIMARY HUMAN CELLS OVER CELL LINES
5.2.1.3 INCREASING DEMAND FOR MONOCLONAL ANTIBODIES
5.2.1.4 RAPID GROWTH IN BIOTECHNOLOGY AND BIOPHARMACEUTICAL INDUSTRIES
・ FIGURE 20 GLOBAL PHARMACEUTICAL R&D SPENDING, 2014–2028
5.2.1.5 GROWING FOCUS ON PERSONALIZED MEDICINE
・ TABLE 7 GROWTH IN NUMBER OF PERSONALIZED MEDICATIONS, 2015–2022
5.2.1.6 GOVERNMENT INVESTMENTS FOR CELL-BASED RESEARCH
5.2.2 RESTRAINTS
5.2.2.1 CONCERNS REGARDING PRIMARY CELL CULTURE CONTAMINATION
5.2.2.2 ETHICAL CONCERNS REGARDING RESEARCH IN CELL BIOLOGY
5.2.3 OPPORTUNITIES
5.2.3.1 ADVANCING BIOMEDICAL RESEARCH USING PRIMARY CELLS IN 3D CULTURES 56
5.2.4 CHALLENGES
5.2.4.1 SOURCING AND AVAILABILITY OF PRIMARY CELLS
5.3 REGULATORY ANALYSIS
5.3.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.4 PRICING ANALYSIS
・ TABLE 8 AVERAGE PRICE OF PRIMARY CELL PRODUCTS, BY KEY PLAYER (USD)
5.5 VALUE CHAIN ANALYSIS
・ FIGURE 21 MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASE
5.6 SUPPLY CHAIN ANALYSIS
・ FIGURE 22 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES
5.7 ECOSYSTEM ANALYSIS
・ FIGURE 23 ECOSYSTEM ANALYSIS OF PRIMARY CELLS MARKET
・ TABLE 9 PRIMARY CELLS MARKET ECOSYSTEM
5.8 KEY CONFERENCES & EVENTS, 2023–2024
・ TABLE 10 PRIMARY CELLS MARKET: LIST OF CONFERENCES & EVENTS
5.9 TECHNOLOGY ANALYSIS
5.10 PORTER’S FIVE FORCES ANALYSIS
・ TABLE 11 PRIMARY CELLS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.10.1 THREAT OF NEW ENTRANTS
5.10.2 THREAT OF SUBSTITUTES
5.10.3 BARGAINING POWER OF SUPPLIERS
5.10.4 BARGAINING POWER OF BUYERS
5.10.5 INTENSITY OF COMPETITIVE RIVALRY
5.11 KEY STAKEHOLDERS & BUYING CRITERIA
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
・ FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PRIMARY CELL PRODUCTS
5.11.2 BUYING CRITERIA FOR PRIMARY CELLS
・ FIGURE 25 KEY BUYING CRITERIA FOR END USERS
6 PRIMARY CELLS MARKET, BY TYPE
6.1 INTRODUCTION
・ TABLE 12 PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION)
6.2 HEMATOPOIETIC CELLS
6.2.1 INCREASING CANCER RESEARCH & FUNDING TO PROPEL MARKET GROWTH
・ TABLE 13 TYPES OF HEMATOPOIETIC CELLS 70
・ TABLE 14 HEMATOPOIETIC CELLS MARKET, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 15 NORTH AMERICA: HEMATOPOIETIC CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 16 EUROPE: HEMATOPOIETIC CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 17 ASIA PACIFIC: HEMATOPOIETIC CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 DERMATOCYTES
6.3.1 RISING PREVALENCE OF MELANOMA TO BOOST DEMAND
・ TABLE 18 DERMATOCYTES MARKET, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 19 NORTH AMERICA: DERMATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 20 EUROPE: DERMATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 21 ASIA PACIFIC: DERMATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.4 GASTROINTESTINAL CELLS
6.4.1 GROWING INCIDENCE OF STOMACH CANCER TO BOLSTER GROWTH
・ TABLE 22 GASTROINTESTINAL CELLS MARKET, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 23 NORTH AMERICA: GASTROINTESTINAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 24 EUROPE: GASTROINTESTINAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 25 ASIA PACIFIC: GASTROINTESTINAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.5 HEPATOCYTES 75
・ TABLE 26 GLOBAL LIVER DISORDER INCIDENCE
・ TABLE 27 HEPATOCYTES MARKET, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 28 NORTH AMERICA: HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 29 EUROPE: HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 30 ASIA PACIFIC: HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 31 HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
6.5.1 CRYOPRESERVED HEPATOCYTES
6.5.1.1 LONGER LIFESPAN OF CRYOPRESERVED HEPATOCYTES THAN FRESH HEPATOCYTES TO DRIVE MARKET GROWTH
・ TABLE 32 CRYOPRESERVED HEPATOCYTES MARKET, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 33 NORTH AMERICA: CRYOPRESERVED HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 34 EUROPE: CRYOPRESERVED HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 35 ASIA PACIFIC CRYOPRESERVED HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.5.2 FRESH HEPATOCYTES 80
6.5.2.1 STRINGENT REGULATIONS AND LIMITED AVAILABILITY OF FRESH HEPATOCYTES TO LIMIT MARKET GROWTH
・ TABLE 36 FRESH HEPATOCYTES MARKET, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 37 NORTH AMERICA: FRESH HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 38 EUROPE: FRESH HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 39 ASIA PACIFIC: FRESH HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.6 LUNG CELLS 82
6.6.1 INCREASING RATE OF LUNG CANCER & COPD TO DRIVE DEMAND FOR LUNG CELLS
・ TABLE 40 LUNG CELLS MARKET, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 41 NORTH AMERICA: LUNG CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 42 EUROPE: LUNG CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 43 ASIA PACIFIC: LUNG CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.7 RENAL CELLS 84
6.7.1 LACK OF AVAILABILITY OF EFFECTIVE RENAL THERAPIES TO PROPEL MARKET GROWTH
・ TABLE 44 RENAL CELLS MARKET, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 45 NORTH AMERICA: RENAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 46 EUROPE: RENAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 47 ASIA PACIFIC: RENAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.8 HEART CELLS 85
6.8.1 HIGH INCIDENCE OF CARDIOVASCULAR DISEASES TO SUPPORT GROWTH
・ TABLE 48 HEART CELLS MARKET, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 49 NORTH AMERICA: HEART CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 50 EUROPE: HEART CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 51 ASIA PACIFIC: HEART CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.9 MUSCULOSKELETAL CELLS
6.9.1 RISING INCIDENCE OF MUSCULOSKELETAL DISORDERS TO PROPEL MARKET GROWTH
・ TABLE 52 MUSCULOSKELETAL CELLS MARKET, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 53 NORTH AMERICA: MUSCULOSKELETAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 54 EUROPE: MUSCULOSKELETAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 55 ASIA PACIFIC: MUSCULOSKELETAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.10 OTHER PRIMARY CELLS
・ TABLE 56 OTHER PRIMARY CELLS MARKET, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 57 NORTH AMERICA: OTHER PRIMARY CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 58 EUROPE: OTHER PRIMARY CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 59 ASIA PACIFIC: OTHER PRIMARY CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7 PRIMARY CELLS MARKET, BY ORIGIN
7.1 INTRODUCTION
・ TABLE 60 PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
7.2 HUMAN PRIMARY CELLS
7.2.1 INCREASING PREVALENCE OF CANCER TO SUPPORT MARKET GROWTH
・ TABLE 61 HUMAN PRIMARY CELLS MARKET, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 62 NORTH AMERICA: HUMAN PRIMARY CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 63 EUROPE: HUMAN PRIMARY CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 64 ASIA PACIFIC: HUMAN PRIMARY CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 ANIMAL PRIMARY CELLS
7.3.1 RISING INVESTMENTS IN ANIMAL CELL RESEARCH TO PROPEL MARKET GROWTH
・ TABLE 65 ANIMAL PRIMARY CELLS MARKET, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 66 NORTH AMERICA: ANIMAL PRIMARY CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 67 EUROPE: ANIMAL PRIMARY CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 68 ASIA PACIFIC: ANIMAL PRIMARY CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
8 PRIMARY CELLS MARKET, BY END USER
8.1 INTRODUCTION
・ TABLE 69 PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION)
8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS
8.2.1 INCREASING INVESTMENTS IN CELL-BASED RESEARCH TO DRIVE MARKET GROWTH
・ TABLE 70 PRIMARY CELLS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 71 NORTH AMERICA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY COUNTRY, 2021–2028 (USD MILLION) 99
・ TABLE 72 EUROPE: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY COUNTRY, 2021–2028 (USD MILLION) 99
・ TABLE 73 ASIA PACIFIC: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY COUNTRY, 2021–2028 (USD MILLION) 100
8.3 ACADEMIC & RESEARCH INSTITUTES
8.3.1 INCREASING GOVERNMENT FUNDING FOR RESEARCH AND HIGH PREVALENCE OF CANCER TO FAVOR MARKET GROWTH
・ TABLE 74 PRIMARY CELLS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 75 NORTH AMERICA: PRIMARY CELLS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 76 EUROPE: PRIMARY CELLS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 101
・ TABLE 77 ASIA PACIFIC: PRIMARY CELLS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
8.4 OTHER END USERS
・ TABLE 78 PRIMARY CELLS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
・ TABLE 79 NORTH AMERICA: PRIMARY CELLS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 80 EUROPE: PRIMARY CELLS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 81 ASIA PACIFIC: PRIMARY CELLS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
9 PRIMARY CELLS MARKET, BY REGION
9.1 INTRODUCTION
・ TABLE 82 PRIMARY CELLS MARKET, BY REGION, 2021–2028 (USD MILLION)
9.2 NORTH AMERICA
・ FIGURE 26 NORTH AMERICA: PRIMARY CELLS MARKET SNAPSHOT
・ TABLE 83 NORTH AMERICA: PRIMARY CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 84 NORTH AMERICA: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
・ TABLE 85 NORTH AMERICA: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 86 NORTH AMERICA: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 87 NORTH AMERICA: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2.1 US
9.2.1.1 HIGH R&D SPENDING AND GROWING SUPPORT FOR STEM CELL RESEARCH TO DRIVE MARKET GROWTH
・ TABLE 88 US: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
・ TABLE 89 US: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 90 US: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 91 US: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2.2 CANADA
9.2.2.1 PRESENCE OF ADVANCED R&D INFRASTRUCTURE TO BOOST MARKET
・ TABLE 92 CANADA: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
・ TABLE 93 CANADA: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 94 CANADA: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 95 CANADA: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2.3 NORTH AMERICA: IMPACT OF RECESSION
9.3 EUROPE
・ TABLE 96 EUROPE: PRIMARY CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 97 EUROPE: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
・ TABLE 98 EUROPE: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 99 EUROPE: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 100 EUROPE: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.1 UK
9.3.1.1 GROWTH IN LIFE SCIENCE INDUSTRY TO FUEL MARKET GROWTH
・ TABLE 101 UK: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
・ TABLE 102 UK: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 103 UK: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 104 UK: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.2 GERMANY
9.3.2.1 INCREASING LIFE SCIENCE RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH
・ TABLE 105 GERMANY: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
・ TABLE 106 GERMANY: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 107 GERMANY: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 108 GERMANY: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.3 FRANCE
9.3.3.1 ROBUST BIOTECHNOLOGY INFRASTRUCTURE TO SUPPORT GROWTH
・ TABLE 109 FRANCE: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
・ TABLE 110 FRANCE: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 111 FRANCE: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 112 FRANCE: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.4 ITALY
9.3.4.1 INCREASING NUMBER OF CELL BIOLOGY SEMINARS AND CONFERENCES TO FUEL ADOPTION OF PRIMARY CELLS
・ TABLE 113 ITALY: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
・ TABLE 114 ITALY: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 115 ITALY: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 116 ITALY: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.5 REST OF EUROPE
・ TABLE 117 REST OF EUROPE: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
・ TABLE 118 REST OF EUROPE: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 119 REST OF EUROPE: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 120 REST OF EUROPE: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.6 EUROPE: IMPACT OF RECESSION
9.4 ASIA PACIFIC
・ FIGURE 27 ASIA PACIFIC: PRIMARY CELLS MARKET SNAPSHOT
・ TABLE 121 ASIA PACIFIC: PRIMARY CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
・ TABLE 122 ASIA PACIFIC: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
・ TABLE 123 ASIA PACIFIC: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 124 ASIA PACIFIC: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 125 ASIA PACIFIC: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.1 CHINA
9.4.1.1 GROWING FOCUS ON CANCER THERAPEUTICS-RELATED RESEARCH TO BOLSTER GROWTH
・ TABLE 126 CHINA: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
・ TABLE 127 CHINA: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 128 CHINA: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 129 CHINA: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.2 JAPAN
9.4.2.1 GOVERNMENT INITIATIVES TO PROPEL MARKET GROWTH IN JAPAN
・ TABLE 130 JAPAN: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
・ TABLE 131 JAPAN: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 132 JAPAN: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 133 JAPAN: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.3 REST OF ASIA PACIFIC
・ TABLE 134 REST OF ASIA PACIFIC: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
・ TABLE 135 REST OF ASIA PACIFIC: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 136 REST OF ASIA PACIFIC: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 137 REST OF ASIA PACIFIC: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.4 ASIA PACIFIC: IMPACT OF RECESSION
9.5 REST OF THE WORLD
・ TABLE 138 REST OF THE WORLD: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION)
・ TABLE 139 REST OF THE WORLD: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 140 REST OF THE WORLD: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION)
・ TABLE 141 REST OF THE WORLD: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION)
9.5.1 REST OF THE WORLD: IMPACT OF RECESSION
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
・ FIGURE 28 PRIMARY CELLS MARKET: STRATEGIES ADOPTED
10.3 REVENUE SHARE ANALYSIS
・ FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS (2019–2022)
10.4 MARKET SHARE ANALYSIS
・ FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
・ TABLE 142 PRIMARY CELLS MARKET: DEGREE OF COMPETITION
10.5 COMPANY EVALUATION QUADRANT
・ FIGURE 31 PRIMARY CELLS MARKET: COMPANY EVALUATION MATRIX, 2022
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS
10.6.1 PRODUCT FOOTPRINT OF COMPANIES (25 COMPANIES)
・ TABLE 143 PRIMARY CELLS MARKET: PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS
10.6.2 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES)
・ TABLE 144 PRIMARY CELLS MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS
10.7 COMPANY EVALUATION QUADRANT: START-UPS/SMES
・ FIGURE 32 PRIMARY CELLS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
10.7.1 PROGRESSIVE COMPANIES
10.7.2 STARTING BLOCKS
10.7.3 RESPONSIVE COMPANIES
10.7.4 DYNAMIC COMPANIES
10.8 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
・ TABLE 145 PRIMARY CELLS MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
・ TABLE 146 PRIMARY CELLS MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
10.9 COMPETITIVE SCENARIO AND TRENDS
10.9.1 PRODUCT LAUNCHES 152
・ TABLE 147 PRIMARY CELLS MARKET: PRODUCT LAUNCHES, JANUARY 2020–JUNE 2023
10.9.2 DEALS
・ TABLE 148 PRIMARY CELLS MARKET: DEALS, JANUARY 2020–JUNE 2023
10.9.3 OTHER DEVELOPMENTS
・ TABLE 149 PRIMARY CELLS MARKET: OTHER DEVELOPMENTS, JANUARY 2020–JUNE 2023
11 COMPANY PROFILES
11.1 MAJOR PLAYERS
(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW)*
11.1.1 THERMO FISHER SCIENTIFIC, INC.
・ TABLE 150 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
・ FIGURE 33 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
11.1.2 MERCK KGAA
・ TABLE 151 MERCK KGAA: COMPANY OVERVIEW
・ FIGURE 34 MERCK KGAA: COMPANY SNAPSHOT (2022)
・ TABLE 152 OTHER DEVELOPMENTS
11.1.3 CORNING INCORPORATED
・ TABLE 153 CORNING INCORPORATED: BUSINESS OVERVIEW
・ FIGURE 35 CORNING INCORPORATED: COMPANY SNAPSHOT (2022)
11.1.4 LONZA GROUP
・ TABLE 154 LONZA GROUP: BUSINESS OVERVIEW
・ FIGURE 36 LONZA GROUP: COMPANY SNAPSHOT (2022)
・ TABLE 155 PRODUCT LAUNCHES
11.1.5 CHARLES RIVER LABORATORIES, INC.
・ TABLE 156 CHARLES RIVER LABORATORIES, INC.: BUSINESS OVERVIEW
・ FIGURE 37 CHARLES RIVER LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
・ TABLE 157 ACQUISITIONS
11.1.6 PROMOCELL GMBH
・ TABLE 158 PROMOCELL GMBH: BUSINESS OVERVIEW
・ TABLE 159 PRODUCT LAUNCHES
11.1.7 AMERICAN TYPE CULTURE COLLECTION (ATCC)
・ TABLE 160 AMERICAN TYPE CULTURE COLLECTION (ATCC): BUSINESS OVERVIEW
11.1.8 CELL BIOLOGICS, INC.
・ TABLE 161 CELL BIOLOGICS, INC.: BUSINESS OVERVIEW
11.1.9 ZENBIO, INC.
・ TABLE 162 ZENBIO, INC.: BUSINESS OVERVIEW
11.1.10 STEMCELL TECHNOLOGIES, INC. 187
・ TABLE 163 STEMCELL TECHNOLOGIES, INC.: BUSINESS OVERVIEW
11.1.11 ALLCELLS
・ TABLE 164 ALLCELLS: BUSINESS OVERVIEW 193
11.1.12 IXCELLS BIOTECHNOLOGIES
・ TABLE 165 IXCELLS BIOTECHNOLOGIES: BUSINESS OVERVIEW
・ TABLE 166 AGREEMENTS
11.1.13 NEUROMICS
・ TABLE 167 NEUROMICS: BUSINESS OVERVIEW 201
*DETAILS ON BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.
11.2 OTHER COMPANIES
11.2.1 AXOL BIOSCIENCE LTD.
・ TABLE 168 AXOL BIOSCIENCE LTD.: COMPANY OVERVIEW
11.2.2 STEMEXPRESS
・ TABLE 169 STEMEXPRESS: COMPANY OVERVIEW
11.2.3 BIOIVT
・ TABLE 170 BIOIVT: COMPANY OVERVIEW
11.2.4 SCIENCELL RESEARCH LABORATORIES, INC.
・ TABLE 171 SCIENCELL RESEARCH LABORATORIES, INC.: COMPANY OVERVIEW
11.2.5 AMSBIO
・ TABLE 172 AMSBIO: COMPANY OVERVIEW
11.2.6 PROMAB BIOTECHNOLOGIES, INC.
・ TABLE 173 PROMAB BIOTECHNOLOGIES, INC.: COMPANY OVERVIEW
11.2.7 CREATIVE BIOARRAY 209
・ TABLE 174 CREATIVE BIOARRAY: COMPANY OVERVIEW
11.2.8 BPS BIOSCIENCE, INC.
・ TABLE 175 BPS BIOSCIENCE, INC.: COMPANY OVERVIEW
11.2.9 EPITHELIX
・ TABLE 176 EPITHELIX: COMPANY OVERVIEW 212
11.2.10 REACHBIO RESEARCH LABS
・ TABLE 177 REACHBIO RESEARCH LABS: COMPANY OVERVIEW
11.2.11 ACCEGEN
・ TABLE 178 ACCEGEN: COMPANY OVERVIEW
11.2.12 KOSHEEKA
・ TABLE 179 KOSHEEKA: COMPANY OVERVIEW 215